Cancer cells being destroyed by immunotherapy.
(Source: Adobe Stock)

Discover BioVaxys’ innovative DPX™ platform, a cutting-edge lipid-based delivery system transforming immunotherapy. This video explores how the company’s proprietary technology encapsulates diverse bioactive molecules, enhancing and sustaining immune responses. Learn how BioVaxys is leveraging this groundbreaking platform to potentially revolutionize vaccines and treatments.

To keep up with the latest developments from the company, visit https://www.biovaxys.com/

This is third-party content provided by BioVaxys Technology Corp. (CSE:BIOV). Please see full disclaimer here.

Join the discussion: Find out what everybody’s saying about this company on the BioVaxys Technology Corp. Bullboard investor discussion forum, and check out the rest of Stockhouse’s stock forums and message boards.

(Top photo: Adobe Stock)

More From The Market Online
A Canadian flag with stock charts

@ the Bell: TSX slips from its peak

Canada’s main stock index dropped from its record peak. The Bank of Canada will announce its monetary policy decision on Wednesday.
A plasma torch cutting metal

ESG stock PyroGenesis nearly doubles backlog with C$27M deal

PyroGenesis (TSX:PYR), an ESG stock focused on industrial technology, signs a three-year, C$27 million contract with an existing U.S. client.
doctor pointing finger to CT scans

Quantum BioPharma sues CIBC and RBC seeking $700M in damages

A U.S. legal firm claims it has evidence of a market manipulation scheme that caused substantial damages to Quantum BioPharma (CSE:QNTM).

Datametrex AI and CEO part ways amid poor stock performance

Datametrex AI (TSXV:DM) CEO Marshall Gunter resigns following the company's poor financials and stock performance.